Skip to content

Clinical Observation on the Therapeutic Effect of Acupuncture in the Treatment of Psoas Major Injury Syndrome

Clinical Observation on the Therapeutic Effect of Acupuncture in the Treatment of Psoas Major Injury Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002255
Enrollment
Unknown
Registered
2025-11-21
Start date
2025-07-04
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoas Major Injury Syndrome

Interventions

Control group:Diclofenac sodium enteric-coated capsules, 50 mg per dose, orally, twice daily, for 2 consecutive weeks.
Intervention group:Acupuncture: Acupoints include Shiqizhuixue (EX-B8), Yaoyi (EX-B7), BL23, BL25, BL52, BL40, and Ashi points. After achieving Deqi, needles are retained for 30 minutes, once daily, s

Sponsors

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Meet the following clinical diagnostic criteria for psoas major injury syndrome (confirmed by physical and imaging examination): (1) Main symptom: Deep groin pain that aggravates during hip extension (e.g., walking, running, climbing stairs); (2) Positive specific physical signs: Positive Thomas Test and/or Resisted Hip Flexion Test; (3) Imaging support (meet one of the following): Musculoskeletal ultrasonography indicates psoas tendon edema, thickening, peritendinous effusion, or partial tear; Lumbar spine or hip magnetic resonance imaging indicates abnormal psoas morphology, increased signal intensity (edema), or perifascial edema. (4) Exclusion of other pathologies that may cause groin pain. 2.Aged between 25 and 55 years, regardless of gender; 3.No participation in other clinical trials within the past 3 months; 4.Voluntary participation with signed informed consent and ability to comply with trial requirements.

Exclusion criteria

Exclusion criteria: 1.Patients with other severe diseases; 2.Patients with systemic infections; 3.Patients with lumbar spondylolisthesis, isthmic defect, or spinal canal stenosis; 4.Patients taking anticoagulants or immunosuppressants; 5.Patients allergic to non-steroidal anti-inflammatory drugs (NSAIDs).

Design outcomes

Primary

MeasureTime frame
Short-Form McGill Pain Questionnaire (SF-MPQ) score;Roland-Morris Disability Questionnaire (RMDQ) score;Clinical efficacy evaluation;

Countries

China

Contacts

Public ContactHuaize Wang

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

1368918930@qq.com+86 159 2240 1088

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026